XM does not provide services to residents of the United States of America.
C
C

CaraTherapeutics

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Cara Therapeutics Inc <CARA.OQ> expected to post a loss of 25 cents a share - Earnings Preview

Cara Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview Cara Therapeutics Inc CARA.OQ CARA.O is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024 The Stamford Connecticut-based company is expected to report a 66.8% decrease in revenue to $1.616 million from $4.87 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
C

CSL Limited Reports 13.5% Stake In Cara Therapeutics

BRIEF-CSL Limited Reports 13.5% Stake In Cara Therapeutics Oct 30 (Reuters) - CSL Limited: CSL LIMITED REPORTS 13.5% STAKE IN CARA THERAPEUTICS INC AS OF OCT 23 - SEC FILING Source text: [ID:n0001193125-24-247585]
C

Cara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Cara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary Cara Therapeutics Inc CARA.OQ reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of five analysts for the quarter was for a loss of 27 cents per share.
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.